Breast Cancer Staging Without PET-CT: A Practical Work-Up

Breast cancer staging without PET-CT is possible. For a small tumour with no palpable axillary nodes, a chest X-ray and an abdominal ultrasound are enough. For larger or node-positive disease, a whole-abdomen ultrasound, a chest X-ray and a bone scan or a skeletal survey of plain X-rays give a workable picture. Dr. Rajesh Kumar Jain calls this less accurate than PET-CT but optimal when resources are limited.

Staging matters because, in the words of Dr. Rajesh Kumar Jain, Principal Director - Surgical Oncology, BLK-Max Super Speciality Hospital, New Delhi, India, the stage has to be known to plan the treatment. For doctors in countries where PET-CT is scarce, the practical question is not whether to stage but how to stage well enough with the tools at hand, and when the case justifies referral for a fuller evaluation. This article sets out his approach, from a working clinical staging system to the first treatment decision. The steps that come before staging, imaging and biopsy, are covered in the complete guide to breast cancer diagnosis and surgery.

A working staging system for the clinic

Formal breast cancer staging uses the TNM system: the size and local extent of the tumour (T), the spread to regional lymph nodes (N) and distant metastasis (M). Dr. Jain offered a simplified version for everyday clinical use, which he was clear is not technically exact but is practical:

• Stage I: a lump of 2 cm or less.
• Stage II: a lump of more than 2 cm, with some small palpable lymph nodes in the axilla.
• Stage III: a large tumour with skin involvement, such as ulceration, a wound, discharge or a peau d'orange (orange-peel) appearance of the skin, or bulky axillary nodes.
• Stage IV: spread to distant organs, typically the liver, lungs or bones, alone or in combination.

This shorthand is enough to decide how far the staging investigations need to go.

Is PET-CT needed for early breast cancer?

Not for a small tumour with no palpable axillary nodes. Dr. Jain does not apply the same staging tests to every patient: the intensity of the work-up rises with the size of the tumour and the state of the axilla.

Small tumour, no palpable nodes: chest X-ray and abdominal ultrasound

For a T1 tumour (2 cm or less) with no palpable axillary nodes in a woman in good health, the picture is one of early breast cancer, and a PET-CT scan is not needed. A chest X-ray and an ultrasound of the abdomen, which looks for liver metastasis and also assesses the ovaries, are sufficient.

Tumour larger than 2 cm, palpable nodes or bulky disease: assess the bones

Once the tumour is larger than 2 cm or the axillary nodes are palpable, the bones must be assessed in addition to the lungs and liver. Historically this meant a technetium radionuclide bone scan, which is not available in many countries. In Dr. Jain's practice, bone scans are now rarely done because PET-CT has replaced them: for a lesion larger than 2 cm, palpable nodes or bulky disease, his advice is to obtain a PET-CT if at all possible.

Breast cancer staging without PET-CT: the low-resource work-up

Where PET-CT cannot be obtained, Dr. Jain's alternative work-up covers each common site of spread with a widely available test.

Why the whole abdomen, not the upper abdomen

Dr. Jain specifically advises against limiting the ultrasound to the upper abdomen. The liver is the main concern, but the ovaries and uterus also need to be seen, so the scan should cover the whole abdomen.

Skeletal survey or bone scan?

A skeletal survey is a series of plain X-rays that covers the spine, the skull and the limbs. It is the bone-staging option of last resort: simple, cheap and available almost everywhere, but less sensitive than a bone scan or PET-CT.

The trade-off, stated plainly

Dr. Jain was candid that CT of the chest and abdomen with a skeletal survey is "not actually optimum", and that the simple X-ray and ultrasound approach may miss disease that PET-CT would detect. His conclusion was nonetheless clear: when resources are limited, this work-up should be regarded as optimal. For a lump larger than 2 cm, or any more advanced presentation, PET-CT remains the advisable test, and where it cannot be done locally the patient can be referred for a complete evaluation with PET-CT.

Pleural effusion at staging: is it metastasis?

A pleural effusion found at staging does not by itself prove metastatic disease. A doctor in the session described a patient with a breast lump smaller than 2 cm, no axillary lymphadenopathy, a triple-negative biopsy and a left pleural effusion on the chest X-ray. The question was whether the effusion meant metastatic disease.

Dr. Jain's reasoning is a useful lesson in reading staging results against the clinical picture. With such a small primary and no axillary nodes, he considered it unlikely that the effusion was metastatic, and possibly unrelated to the breast cancer altogether. His recommended steps were:

1. Image the chest properly: a PET-CT if possible, or at least a contrast-enhanced CT scan of the chest, to look for lung metastasis associated with the effusion.
2. Sample the fluid: drain the pleural fluid and send it for cytology to establish whether it is malignant.
3. Consider the alternatives: the effusion may be tubercular or have another cause entirely.

The broader point is that an isolated abnormal finding should not upstage a patient to metastatic disease, and remove the option of curative treatment, without proof.

Chemotherapy or surgery first: how staging sets the first treatment

Staging is combined with the receptor profile of the biopsy to decide what comes first: chemotherapy or surgery. Dr. Jain's framework was set out in answer to a question many referring doctors ask, whether chemotherapy can be started in the patient's home country before referral.

Neoadjuvant chemotherapy: the two indications

In Dr. Jain's practice, neoadjuvant chemotherapy, meaning chemotherapy given before surgery, is indicated in two situations:

1. Triple-negative breast cancer, even when early, because it is very aggressive. Chemotherapy is given for around four and a half to five months, the response is reassessed, and surgery and then radiotherapy follow.
2. Locally advanced breast cancer.

For ER-positive, HER2-negative early breast cancer, surgery is done first.

What is locally advanced breast cancer?

Dr. Jain defines locally advanced breast cancer by any of the following at presentation:

• a tumour larger than 5 cm (T3 or above);
• ulceration of the skin;
• peau d'orange;
• satellite nodules in the skin;
• bulky axillary lymph nodes;
• a palpable supraclavicular lymph node.

In locally advanced disease, chemotherapy comes first, and surgery follows after around four to four and a half months of chemotherapy.

Metastatic and oligometastatic breast cancer

In metastatic breast cancer, treatment is systemic only: chemotherapy or hormone therapy, with no surgery. Dr. Jain identifies one exception, oligometastatic disease, meaning one or two small bone metastases, or a single small metastasis in the lung or in the liver. He treats oligometastatic breast cancer in the same way as locally advanced disease: chemotherapy, followed by surgery and then radiotherapy. Treating oligometastatic disease with curative intent is an evolving approach that is decided case by case by a multidisciplinary tumour board.

For a protocol view of the same decisions, organised by subtype and stage, see Dr. Jain's later breast cancer treatment protocol by stage and subtype, from his September 2026 session.

Starting chemotherapy at home and deciding when to refer

The question that opened this discussion was practical: can chemotherapy begin before the patient travels? Dr. Jain's answer follows from the framework above. Neoadjuvant chemotherapy is appropriate for triple-negative and locally advanced disease, and whatever can be done well in the patient's own country should be done there.

His recommendation is to discuss the case first. With the patient's records available, a video consultation can settle the best way forward, and he will say without bias which patients need treatment in New Delhi. In his words, it is always better to "discuss, discuss and discuss" for the benefit of patients. The questions raised during the session are collected in the live discussion from this masterclass.

Once staging is complete and the disease is operable, the next decision is the operation itself. How Dr. Jain chooses between breast conservation and mastectomy, and how he manages the axilla, is covered in breast conservation surgery vs mastectomy. The full pathway, from the first imaging test to adjuvant therapy, is in the complete guide to breast cancer diagnosis and surgery, and related guides sit in the oncology specialty hub.